Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT Trial at the 2021 SNO Annual MeetingBusiness Wire • 11/20/21
Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS)Business Wire • 11/19/21
Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/05/21
Will Puma Biotech (PBYI) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 10/28/21
Puma Biotechnology to Present at the Cantor Virtual Global Healthcare ConferenceBusiness Wire • 09/21/21
Puma Biotechnology to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceBusiness Wire • 09/07/21
Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/06/21
Puma Biotech's Nerlynx Wins Canadian Approval In HER2-Positive Metastatic Breast CancerBenzinga • 07/06/21
Knight Therapeutics Announces Health Canada Approval for NERLYNX® (Neratinib) to Treat HER2-Positive Metastatic Breast CancerGlobeNewsWire • 07/06/21
FDA Approves Dose Escalation Label Update for Puma Biotechnology's NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast CancerBusiness Wire • 07/01/21
Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual MeetingBusiness Wire • 06/04/21
Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual MeetingBusiness Wire • 06/04/21
Puma Biotechnology Presents Data from the Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer Patients at the Virtual 2021 ASCO Annual MeetingBusiness Wire • 06/04/21
Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2021 ASCO Annual MeetingBusiness Wire • 05/19/21
Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/07/21